JPH04209711A - Production of hydroxyapatite - Google Patents
Production of hydroxyapatiteInfo
- Publication number
- JPH04209711A JPH04209711A JP2337838A JP33783890A JPH04209711A JP H04209711 A JPH04209711 A JP H04209711A JP 2337838 A JP2337838 A JP 2337838A JP 33783890 A JP33783890 A JP 33783890A JP H04209711 A JPH04209711 A JP H04209711A
- Authority
- JP
- Japan
- Prior art keywords
- buffer solution
- hap
- slurry
- phosphoric acid
- tris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 45
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 23
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000007983 Tris buffer Substances 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims abstract description 13
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000000920 calcium hydroxide Substances 0.000 claims abstract description 12
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims abstract description 12
- 239000002002 slurry Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000011261 inert gas Substances 0.000 claims abstract description 4
- 239000006173 Good's buffer Substances 0.000 claims abstract 3
- 239000011575 calcium Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 abstract description 5
- 239000007789 gas Substances 0.000 abstract description 4
- ZIRURAJAJIQZFG-UHFFFAOYSA-N 1-aminopropane-1-sulfonic acid Chemical class CCC(N)S(O)(=O)=O ZIRURAJAJIQZFG-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000007795 chemical reaction product Substances 0.000 abstract 2
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 abstract 1
- 235000011116 calcium hydroxide Nutrition 0.000 abstract 1
- 230000032683 aging Effects 0.000 description 9
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000010304 firing Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Dental Prosthetics (AREA)
Abstract
Description
【発明の詳細な説明】
(技術分野)
本発明は、ハイドロキシアパタイトの改善された製造法
に係り、特に再現性よく、理論組成比Ca/P=1.6
7の微結晶ハイドロキシアパタイトを製造する手法に関
するものである。DETAILED DESCRIPTION OF THE INVENTION (Technical Field) The present invention relates to an improved method for producing hydroxyapatite, which has particularly good reproducibility and a theoretical composition ratio of Ca/P=1.6.
The present invention relates to a method for producing microcrystalline hydroxyapatite No. 7.
(背景技術)
従来から、ハイドロキシアパタイト(以下、HApと略
称する)は生体親和材料として好適に用いられており、
それを得るための湿式合成法において、その出発原料や
合成方法に関して数多くの提案が為されてきているが、
なかでも、水酸化カルシウムとリン酸とを用いて合成す
る方法が、原料コストが安価であるところから、工業的
に有利な方法とされている。(Background Art) Hydroxyapatite (hereinafter abbreviated as HAp) has traditionally been suitably used as a biocompatible material.
Many proposals have been made regarding the starting materials and synthesis methods for wet synthesis methods for obtaining it.
Among these, the method of synthesis using calcium hydroxide and phosphoric acid is considered to be an industrially advantageous method because the raw material cost is low.
ところで、そのような方法において、Ca / P比は
、反応時のpH、リン酸の滴下速度、熟成温度、熟成時
間、その他の因子等によって影響を受は易いところから
、再現性よく合成することは難しく、加えて、HApは
、酸性溶液中で溶解度が著しく増加するため、反応時の
pHを塩基性側に保持することが必要とされているので
ある。By the way, in such a method, the Ca/P ratio is easily influenced by the pH during the reaction, the dropping rate of phosphoric acid, the aging temperature, the aging time, and other factors, so it is important to synthesize with good reproducibility. In addition, since the solubility of HAp increases significantly in acidic solutions, it is necessary to maintain the pH during the reaction on the basic side.
そこで、そのような問題に対処すべく、(a)反応を二
段階に分けて、−旦Ca欠損型、即ちCa / P比を
理論組成比である1、67より小さくし、その後、不足
分のCaを補填する方法、(b)リン酸の滴下速度を何
段階にも分けて、HApの生成速度を細かく制御する方
法、(C)予めアルカリ溶液を加えて、反応溶液のpH
が酸性側に移動しないようにする方法、等の各種の手法
が提案されているが、それらの方法では、合成工程が複
雑になったり、また生成物がゲル化し易く、濾過・洗浄
が困難となったりする等の問題点が生じている。また、
加水分解によって塩基を発生する有機化合物、例えば尿
素やヘキサメチレンテトラミンを用いる方法も考えられ
ているが、かかる有機化合物を分解するためには、10
0℃程度の温度が必要とされ、更に尿素は分解して炭酸
ガスを発生するために、炭酸アパタイトが生成される等
の問題を内在するものであった。Therefore, in order to deal with such a problem, (a) the reaction was divided into two stages, and the Ca-deficient type, that is, the Ca/P ratio was made smaller than the theoretical composition ratio of 1.67, and then the deficiency was (b) A method of finely controlling the rate of HAp production by dividing the dropping rate of phosphoric acid into several stages; (C) A method of adding an alkaline solution in advance to adjust the pH of the reaction solution.
Various methods have been proposed, such as methods to prevent the migration of ions to the acidic side, but these methods complicate the synthesis process, and the product tends to gel, making filtration and washing difficult. Problems have arisen, such as: Also,
A method using an organic compound that generates a base upon hydrolysis, such as urea or hexamethylenetetramine, has been considered, but in order to decompose such an organic compound, 10
A temperature of about 0° C. is required, and since urea decomposes and generates carbon dioxide gas, there are inherent problems such as the formation of carbonated apatite.
(解決課題)
ここにおいて、本発明は、かかる事情を背景にして為さ
れたものであって、その解決すべき課題とするところは
、上述の如き問題点が悉く解消された、Ca / Pが
理論組成比である1、67のHApを、再現性よく製造
する方法を提供することにある。(Problem to be solved) The present invention has been made against this background, and the problem to be solved is to solve the problem of Ca/P in which all the above-mentioned problems are solved. The object of the present invention is to provide a method for producing HAp having a theoretical composition ratio of 1.67 with good reproducibility.
(解決手段)
そして、本発明は、かかる課題を解決すべく、不活性ガ
ス雰囲気中、撹拌下で、水酸化カルシウムスラリーにリ
ン酸水溶液を滴下して、反応せしめることにより、ハイ
ドロキシアパタイトを合成するに際して、トリス緩衝液
、グツドの緩衝液等の生化学的緩衝液を用いてpHを制
御し、理論組成比のCa/P=1.67を有するハイド
ロキシアパタイトを生成せしめるようにしたところに、
特徴を有するものである。(Solution Means) In order to solve this problem, the present invention synthesizes hydroxyapatite by dropping a phosphoric acid aqueous solution into a calcium hydroxide slurry under stirring in an inert gas atmosphere and causing a reaction. At this time, the pH was controlled using a biochemical buffer such as Tris buffer or Gud's buffer to produce hydroxyapatite having a theoretical composition ratio of Ca/P = 1.67.
It has characteristics.
(具体的説明・作用)
ところで、ハイドロキシアパタイト(HAp)は、Ca
10 (P 04)&(OH)!の化学式を有し、そ
のCa / Pの理論組成比は1.67であるが、歯。(Specific explanation/effect) By the way, hydroxyapatite (HAp)
10 (P 04) & (OH)! It has a chemical formula of 1.67, and its theoretical composition ratio of Ca/P is 1.67.
骨等の生体硬組織を構成するHApは、Ca / P<
1.67の、所謂Ca欠損型HApである。そのため
に、合成HApを人工骨または人工歯根等に使用する場
合には、Ca欠損型HApは、理論組成比を有するHA
pより生体適合性が大きいとされている。しかしながら
、そのように、合成HApを人工骨または人工歯根等に
使用するには、1000°C程度、或いはそれ以上の温
度で焼結させる必要があるが、前記したCa欠損型HA
pは、800°C以上の温度で焼成すると、一部分解し
てリン酸三カルシウムを析出するようになる。一方、理
論組成比Ca/P=1.67を有するHApは、130
0°Cで焼成した後も安定しているところから、HAp
焼結体を作製するためには、Ca / P=1.67を
有するHAp粉末が必要とされるのである。HAp, which constitutes biological hard tissues such as bones, has a concentration of Ca/P<
It is a so-called Ca-deficient HAp of 1.67. Therefore, when synthetic HAp is used for artificial bones or artificial tooth roots, Ca-deficient HAp is
It is said to have greater biocompatibility than p. However, in order to use synthetic HAp for artificial bones or artificial tooth roots, it is necessary to sinter it at a temperature of about 1000°C or higher.
When p is fired at a temperature of 800°C or higher, it partially decomposes and precipitates tricalcium phosphate. On the other hand, HAp with the theoretical composition ratio Ca/P=1.67 is 130
HAp is stable even after firing at 0°C.
In order to produce a sintered body, HAp powder with Ca/P=1.67 is required.
また、一般に、HApを生成すべく、不活性雰囲気中に
て、水酸化カルシウム懸濁液(スラリー)に対して、化
学量論量のリン酸を滴下していくと、その仕込量が60
〜70%まではpH=11.7の一定値を示すが、その
後、急速にPH値が減少し始め、仕込量のリン酸を全て
加え終わった時点では、pH値は4付近となるのである
(第1図参照)。そして、かかるHApの溶解度は、p
Hに強(依存し、酸性側で著しく増大するところから、
生成するHApは、Ca欠損型となり、上述の如く、8
00℃以上の温度での焼成により、リン酸三カルシウム
に移行するようになり、また、塩基性側のpHに制御す
ると、Ca過剰型となって、焼成後にCaOを析出する
のである。このように、HApの組成は、pHにより太
き(変化するところから、HApの組成の制御、換言す
ればCa/P比=1.67のHApを得るためには、中
性付近でのpHの制御が望ましい。Generally, in order to generate HAp, when a stoichiometric amount of phosphoric acid is dropped into a calcium hydroxide suspension (slurry) in an inert atmosphere, the amount charged is 60%.
The pH value shows a constant value of 11.7 until ~70%, but after that, the pH value begins to decrease rapidly, and by the time the entire amount of phosphoric acid has been added, the pH value is around 4. (See Figure 1). And the solubility of such HAp is p
Strongly (depends on H) and increases significantly on the acidic side,
The generated HAp is Ca-deficient, and as mentioned above, 8
Calcination at a temperature of 00° C. or higher causes the transition to tricalcium phosphate, and if the pH is controlled to be on the basic side, it becomes Ca-excessive and precipitates CaO after firing. In this way, the composition of HAp varies depending on the pH, so in order to control the composition of HAp, in other words, to obtain HAp with a Ca/P ratio of 1.67, it is necessary to adjust the pH around neutrality. control is desirable.
そのために、本発明にあっては、水酸化カルシウムとリ
ン酸の水溶液反応によりHApを合成するに際し、トリ
ス緩衝液〔トリス(ヒドロキシメチル)アミノメタンと
強酸、pH=7〜9〕やグツドの緩衝液(アミノプロパ
ンスルボン酸誘導体、pH=6〜11)のような生化学
的緩衝液を用いることにより、反応液のPHが中性域、
一般に7以上、8未満、好ましくは7.0〜7.8の範
囲に制御されるようにされている。Therefore, in the present invention, when synthesizing HAp by an aqueous solution reaction of calcium hydroxide and phosphoric acid, it is necessary to use a Tris buffer [tris(hydroxymethyl)aminomethane and a strong acid, pH = 7 to 9] or a gas buffer. By using a biochemical buffer such as (aminopropane sulfonic acid derivative, pH = 6 to 11), the pH of the reaction solution is in the neutral range,
Generally, it is controlled to be 7 or more and less than 8, preferably in the range of 7.0 to 7.8.
これらの緩衝液は、よく知られているように、pHの中
性付近に緩衝能を有し、金属イオンと殆ど反応せず、ま
たそれ自身生理活性を示さない、細胞膜を通らない、炭
酸ガスを吸収しない等の特徴を有しており、生化学的緩
衝液として広く用いられているものである。なお、トリ
ス緩衝液を用いる場合、トリス(ヒドロキシメチル)ア
ミノメタンCNH2C(CH20H)!、以下トリスと
略称とする〕と、強酸としては、一般には塩酸とが組み
合わされるが、本発明では、リン酸が存在するために、
トリスとリン酸の組合せによる緩衝作用が利用されるこ
ととなる。As is well known, these buffers have a buffering capacity near neutral pH, hardly react with metal ions, do not exhibit physiological activity themselves, do not pass through cell membranes, and do not contain carbon dioxide gas. It is widely used as a biochemical buffer because it does not absorb. In addition, when using Tris buffer, tris(hydroxymethyl)aminomethane CNH2C(CH20H)! , hereinafter abbreviated as Tris] and hydrochloric acid are generally combined as strong acids, but in the present invention, due to the presence of phosphoric acid,
The buffering effect of the combination of Tris and phosphoric acid will be utilized.
そして、本発明においては、所定の不活性ガス雰囲気中
にて、撹拌しつつ、水酸化カルシウムスラリーに、リン
酸水溶液を滴下して、反応せしめる際に、上述の如き所
定の緩衝液を添加することにより、反応液のpHが調整
されるのである。なお、かかる生化学的緩衝液の添加に
ついては、水酸化カルシウム懸濁液(スラリー)中に、
リン酸を加えるに先立って、予め所定量において添加し
て、その後、リン酸を加えるか、或いは先にリン酸を滴
下して、上記制御範囲内の所望のpH値に達せしめた後
、添加することも出来、何れの場合にも、該緩衝液の添
加量に応じて、pHは略一定値に保持され得るところか
ら、略理論組成比Ca/P=1.67を有する微結晶H
Apが再現性よく生成され得るのである。In the present invention, a phosphoric acid aqueous solution is added dropwise to a calcium hydroxide slurry while stirring in a predetermined inert gas atmosphere to cause a reaction, and a predetermined buffer solution as described above is added thereto. This allows the pH of the reaction solution to be adjusted. In addition, regarding the addition of such a biochemical buffer, in the calcium hydroxide suspension (slurry),
Prior to adding phosphoric acid, add it in advance in a predetermined amount, and then add phosphoric acid, or drop phosphoric acid first to reach the desired pH value within the above control range, and then add it. In either case, the pH can be maintained at a substantially constant value depending on the amount of the buffer solution added.
Ap can be generated with good reproducibility.
而して、本発明に従って、上記の如<pHを制御しつつ
、Ca / Pを理論組成比(1,67)として生成さ
れたHApは、その後、適当な時間において熟成され、
更に通常の手法に従って、濾過、乾燥、焼成等の各工程
を経て、各種の用途に用いられるように調製されるので
ある。Thus, according to the present invention, HAp produced as described above with a theoretical composition ratio of Ca/P (1,67) while controlling the pH is then aged for an appropriate time,
Furthermore, it is prepared for various uses through various steps such as filtration, drying, and calcination according to conventional methods.
(実施例)
以下に、本発明の実施例を示し、本発明を更に具体的に
明らかにすることとするが、本発明がそのような実施例
の記載によって何等の制約をも受けるものでないことは
、言うまでもないところである。(Examples) Examples of the present invention are shown below to clarify the present invention more specifically, but the present invention is not limited in any way by the description of such examples. It goes without saying that.
また、本発明には、以下の実施例の他にも・、更には上
記の具体的記述以外にも、本発明の趣旨を逸脱しない限
りにおいて、当業者の知識に基づいて種々なる変更、修
正、改良等を加え得るものであることが、理解されるべ
きである。In addition to the following embodiments and the above-described specific description, the present invention includes various changes and modifications based on the knowledge of those skilled in the art, as long as they do not depart from the spirit of the present invention. It should be understood that improvements and modifications may be made.
実施例 1
酸化カルシウム:414.8gを、窒素気流中、予め脱
炭酸した水:3.M!に加えて水酸化カルシウム懸濁液
とした。そして、この懸濁液を60°Cに加温し、強く
撹拌しながら、リン酸1 mol溶液の4.421をゆ
っくりと滴下し、pH値が7.2に至った時点で、トリ
ス1 mol溶液を370m1.加え、更にリン酸を滴
下した。リン酸の仕込量の全量を加え終わった時点のp
Hは7.2であった。その後、所定時間の間、熟成を続
けた。その熟成時間、pH値、Ca / P比の変化を
、下記第1表に示す。Example 1 Calcium oxide: 414.8 g was previously decarboxylated in a nitrogen stream. Water: 3. M! In addition, it was made into a calcium hydroxide suspension. Then, this suspension was heated to 60°C, and while stirring strongly, 4.421 of a 1 mol solution of phosphoric acid was slowly added dropwise, and when the pH value reached 7.2, 1 mol of Tris was added dropwise. Add the solution to 370 ml. In addition, phosphoric acid was further added dropwise. p at the time when the entire amount of phosphoric acid has been added
H was 7.2. Thereafter, aging continued for a predetermined period of time. The changes in aging time, pH value, and Ca/P ratio are shown in Table 1 below.
第1表
なお、94時間の熟成後のHAp結晶の大きさは、平均
100n100n、5nmであった。Table 1 Note that the average size of the HAp crystals after aging for 94 hours was 100n100n, 5nm.
そして、このような熟成が終了した後、濾過、乾燥せし
め、得られたHAp粉末を1100°Cの温度で焼成し
た。また、得られた焼成体のX線粉末回折線図形(2−
a)を第2図に示した。After completion of such aging, the HAp powder was filtered and dried, and the resulting HAp powder was calcined at a temperature of 1100°C. In addition, the X-ray powder diffraction pattern (2-
a) is shown in Figure 2.
実施例 2
水酸化カルシウム懸濁液にリン酸を滴下するに先立って
、p H= 7.2に制御するに充分なトリス緩衝液を
添加し、その後リン酸を滴下したこと以外は、全て実施
例1と同一の条件で、HApを合成した。熟成によるp
)(とCa / P比の変化を、下記第2表に示す。Example 2 All procedures were carried out except that before adding phosphoric acid to the calcium hydroxide suspension, enough Tris buffer was added to control pH = 7.2, and then phosphoric acid was added dropwise. HAp was synthesized under the same conditions as in Example 1. p due to aging
) (and the changes in Ca/P ratio are shown in Table 2 below.
G;=。G;=.
第2表
また、実施例1と同様に、1100℃の温度にて焼成し
た後のHApのX線粉末回折線図形(2−b)を測定し
、その結果を、第2図に示した。Table 2 Also, as in Example 1, the X-ray powder diffraction pattern (2-b) of HAp after firing at a temperature of 1100° C. was measured, and the results are shown in FIG.
比較例 1
水酸化カルシウム懸濁液にリン酸を滴下して、pH値が
6.0になった時点でトリス緩衝液を添加した。そして
、pH値を6.0に設定した以外は、実施例1と同様の
条件によりHApを合成した。Comparative Example 1 Phosphoric acid was added dropwise to a calcium hydroxide suspension, and when the pH value reached 6.0, a Tris buffer was added. Then, HAp was synthesized under the same conditions as in Example 1 except that the pH value was set to 6.0.
その熟成によるpH及びCa / P比の変化を、下記
第3表に示す。Changes in pH and Ca/P ratio due to aging are shown in Table 3 below.
第3表
そして、実施例1と同様に、濾過により得られた固形分
(HAp)を乾燥し、1100°Cの温度で焼成した。Table 3 Then, in the same manner as in Example 1, the solid content (HAp) obtained by filtration was dried and calcined at a temperature of 1100°C.
その焼成物のX線粉末回折線図形(3−b)を第3図に
示した。The X-ray powder diffraction pattern (3-b) of the fired product is shown in FIG.
かかる図より明らかなように、HApの他に、微量のα
−TCPが共存していることが認められた。As is clear from this figure, in addition to HAp, a small amount of α
-TCP was found to coexist.
比較例 2
水酸化カルシウム懸濁液にリン酸を滴下して、pH値が
8.0になった時点でトリス緩衝液を加え、pH値を8
.0に設定した以外は、実施例1と同様にして、HAp
を合成した。その熟成によるpH及びCa / P比の
変化を、下記第4表に示す。Comparative Example 2 Phosphoric acid was added dropwise to a calcium hydroxide suspension, and when the pH value reached 8.0, Tris buffer was added to lower the pH value to 8.0.
.. HAp was set to 0 in the same manner as in Example 1 except that it was set to 0.
was synthesized. Changes in pH and Ca/P ratio due to aging are shown in Table 4 below.
第4表
また、1100℃にて焼成した後の焼成物のX線粉末回
折線図形(3−a)を第3図に示した。Table 4 Furthermore, the X-ray powder diffraction pattern (3-a) of the fired product after firing at 1100°C is shown in FIG.
かかる図に示されるように、HApの他に、微量のCa
Oが共存していることが認められた。As shown in this figure, in addition to HAp, a trace amount of Ca
The coexistence of O was observed.
比較例 3
トリス緩衝液を添加しないこと以外は、実施例1と同一
条件において、)(Apを合成した。その熟成によるp
H値とCa / P比の変化を下記第5表に示す。Comparative Example 3 Ap was synthesized under the same conditions as in Example 1 except that no Tris buffer was added.
Changes in H value and Ca/P ratio are shown in Table 5 below.
第5表
また、得られたHAp粉末を1100°Cの温度にて焼
成した後、その焼成体のX線粉末回折線図形(3−c)
を第3図に示した。かかる図より、全て、β−TCPに
変化していることが認められた。Table 5 also shows the X-ray powder diffraction pattern (3-c) of the fired product after firing the obtained HAp powder at a temperature of 1100°C.
is shown in Figure 3. From this figure, it was recognized that all of the samples had changed to β-TCP.
(発明の効果)
以上の説明から明らかなように、本発明にあっては、ト
”リス緩衝液、グツドの緩衝液等の生化学的緩衝液を用
いて、反応液のpHを制御することにより、Ca /
Pが理論組成比(1,67)となるようにされていると
ころから、理論組成比のCa/Pを有するハイドロキシ
アパタイトが、複雑な工程を必要とすることなく、また
再現性よく、有利に得られるのである。(Effects of the Invention) As is clear from the above explanation, in the present invention, the pH of the reaction solution can be controlled using a biochemical buffer such as Tris buffer or Gud's buffer. Accordingly, Ca /
Since P is made to have a theoretical composition ratio (1,67), hydroxyapatite having a theoretical composition ratio of Ca/P can be produced without the need for complicated processes and with good reproducibility. You can get it.
第1図は、ハイドロキシアパタイト組成に対するリン酸
の化学量論量とpHとの関係を示すグラフであり、第2
図は、実施例1.2において得られた焼成体のX線粉末
回折線図形であり、第3図は、上記実施例1及び比較例
1〜3において得られた焼成体のX線粉末回折線図形で
ある。
出願人 共立窯業原料株式会社
同 株式会社ニス・ティー・ケー・セラミックス研
究所
第1図
0 20 40 60 80 X)0ハイド0
キシ7ノ?タイト魅成にt′tオるリン鹸の411量g
伽! (%)
第2図
第3図FIG. 1 is a graph showing the relationship between the stoichiometric amount of phosphoric acid and pH for the hydroxyapatite composition;
The figure shows the X-ray powder diffraction pattern of the fired body obtained in Example 1.2, and FIG. 3 shows the X-ray powder diffraction pattern of the fired body obtained in Example 1 and Comparative Examples 1 to 3. It is a line figure. Applicant: Kyoritsu Ceramic Materials Co., Ltd. Niss TK Ceramics Research Institute, Ltd. Figure 1 0 20 40 60 80 X) 0 Hyde 0
Kishi7no? 411g of Rinsen that is perfect for tight charms
Fairy tale! (%) Figure 2 Figure 3
Claims (1)
リーにリン酸水溶液を滴下して、反応せしめることによ
り、ハイドロキシアパタイトを合成するに際して、トリ
ス緩衝液、グッドの緩衝液等の生化学的緩衝液を用いて
pHを制御し、理論組成比のCa/P=1.67を有す
るハイドロキシアパタイトを生成せしめることを特徴と
するハイドロキシアパタイトの製造法。When synthesizing hydroxyapatite by dropping an aqueous phosphoric acid solution into a calcium hydroxide slurry under stirring in an inert gas atmosphere and causing a reaction, biochemical buffers such as Tris buffer and Good's buffer are used. 1. A method for producing hydroxyapatite, which comprises controlling the pH using a method of producing hydroxyapatite having a theoretical composition ratio of Ca/P=1.67.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2337838A JP2989260B2 (en) | 1990-11-30 | 1990-11-30 | Method for producing hydroxyapatite |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2337838A JP2989260B2 (en) | 1990-11-30 | 1990-11-30 | Method for producing hydroxyapatite |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04209711A true JPH04209711A (en) | 1992-07-31 |
JP2989260B2 JP2989260B2 (en) | 1999-12-13 |
Family
ID=18312451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2337838A Expired - Fee Related JP2989260B2 (en) | 1990-11-30 | 1990-11-30 | Method for producing hydroxyapatite |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2989260B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090648A1 (en) * | 2007-01-25 | 2008-07-31 | Meiji University | Cement material and cement |
RU2717275C2 (en) * | 2018-08-22 | 2020-03-19 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | Method of producing granulated hydroxyapatite particles |
CN115718163A (en) * | 2022-11-23 | 2023-02-28 | 西安热工研究院有限公司 | Method for measuring reaction rate of limestone powder for wet flue gas desulfurization and application |
-
1990
- 1990-11-30 JP JP2337838A patent/JP2989260B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008090648A1 (en) * | 2007-01-25 | 2008-07-31 | Meiji University | Cement material and cement |
US8172939B2 (en) | 2007-01-25 | 2012-05-08 | Meiji University | Material for cement, and cement |
RU2717275C2 (en) * | 2018-08-22 | 2020-03-19 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | Method of producing granulated hydroxyapatite particles |
CN115718163A (en) * | 2022-11-23 | 2023-02-28 | 西安热工研究院有限公司 | Method for measuring reaction rate of limestone powder for wet flue gas desulfurization and application |
Also Published As
Publication number | Publication date |
---|---|
JP2989260B2 (en) | 1999-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1297656C (en) | Process of preparing hydroxylapatite | |
US5017518A (en) | Process for producing calcium phosphate ceramics having porous surface | |
JP4354012B2 (en) | Silicon-substituted hydroxyapatite and process for producing the same | |
KR100489549B1 (en) | Low Temperature Calcum Phosphate Apatite and a Method of Its Manufacture | |
JP4540225B2 (en) | Process for producing magnesium and carbonate substituted hydroxyapatite | |
US6428803B1 (en) | Hydroxylapatite gel | |
US5322675A (en) | Method of preparing calcium phosphate | |
JPS6287406A (en) | Production of beta-tricalcium phosphate | |
US6881227B2 (en) | Hydroxylapatite material containing tricalcium phosphate with microporous structure | |
JPH04209711A (en) | Production of hydroxyapatite | |
RU99117701A (en) | AMORPHOUS, CARBONATED AND FLUORINATED HYDROXYAPATITIS FOR DENTAL PASTES AND METHOD FOR ITS PREPARATION | |
US20220380216A1 (en) | Method for producing whitlockite and method for controlling particle size of whitlockite crystal | |
KR960012708B1 (en) | Process for the preparation of hydroxy appatite | |
JPH0461807B2 (en) | ||
JPH0940407A (en) | Production of tetracalcium phosphate | |
JPH0578109A (en) | Method for producing hydroxyapatite | |
KR950004767B1 (en) | Process for producing high purity apatite hydroxide | |
JPH0627025B2 (en) | Hydroxyapatite filter cake dried product | |
WO2000068144A1 (en) | Method for the preparation of carbonated hydroxyapatite compositions | |
EP1717199A1 (en) | Sintered body of titanium compound | |
JPS6366790B2 (en) | ||
KR100275628B1 (en) | Method for preparing crystalline apatite having high purity | |
JPS63100008A (en) | Preparation of tricalcium phosphate | |
JPH0324405B2 (en) | ||
JPH03210271A (en) | Production of biomaterial of calcium phosphate system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |